Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 21, 2004 W.D. Crotty	One Value-Priced Biotech Giant Amgen is a growing cash machine selling at the market's multiple to earnings.
Chemistry World August 27, 2015 Phillip Broadwith	Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases.
The Motley Fool July 28, 2010 Brian Orelli	Fighting Hard to Keep a Blockbuster Sanofi is suing the FDA to take back approval of a competing generic drug. Did you expect something different?
Chemistry World April 4, 2013 Phillip Broadwith	Regeneron expands, creating 400 new jobs US biotech Regeneron has announced that it will expand its corporate headquarters and laboratories in Tarrytown.
The Motley Fool December 26, 2006 Brian Lawler	2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year.
The Motley Fool April 10, 2007 Brian Lawler	Barr Issues a Challenge Barr challenges the patents on one of Sanofi's top drugs.
The Motley Fool December 27, 2010 Brian Orelli	Painful Clinical Hold? Not Really. Regeneron offers the benefits of a full pipeline.
Chemistry World May 14, 2015 Rebecca Trager	Injunction blocks first US biosimilar A US federal circuit court has granted a request by Amgen to temporarily block sales of the first biosimilar product approved by the US Food and Drug Administration
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool November 11, 2009 Brian Orelli	Now That's What I Call a Drug Deal Investors are regenerating their interest in Regeneron Pharmaceuticals after it extended its drug-discovery pact with sanofi-aventis.
The Motley Fool July 18, 2011 Brian Orelli	A $3.6 Billion Franchise at Stake Amgen and Teva settle their patent dispute, and Amgen investors have a little better idea of when the company's $3.6 billion Neupogen and Neulasta franchise might come under attack in the United States.
Chemistry World January 3, 2014 Ben Valsler	Sanofi suffers multiple sclerosis setback French pharmaceutical Sanofi has run into trouble after the US Food and Drug Administration rejected its multiple sclerosis drug Lemtrada (alemtuzumab).
Chemistry World September 4, 2013 Sarah Houlton	Amgen snaps up Onyx in huge biotech deal The $10.4 billion deal gives Amgen access to the recently approved multiple myeloma drug carfilzomib (Kyprolis), plus several other partnered anticancer agents that are already on the market.
The Motley Fool December 11, 2006 Brian Lawler	Weighing In on Sanofi's Acomplia With the future of Sanofi's two top drugs in the hands of the courts, plus any Acomplia approval subject to the whims of the FDA, investors should wait on the sidelines until these judicial and regulatory decisions have been made.
The Motley Fool February 22, 2011 Brian Orelli	A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S.
The Motley Fool March 28, 2008 Brian Lawler	Amgen and Roche Still Duking It Out Amgen threatens to sue Roche for damages.
The Motley Fool February 29, 2008 Brian Lawler	Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs.
InternetNews December 14, 2004 Roy Mark	Court Rules RIM Infringed A federal appeals court ruled today that a district court properly determined that Research in Motion infringed on the patents on NTP, but still sent the case back to the district court for further review of damages.
The Motley Fool August 25, 2008 Brian Lawler	Amgen Gets Its FDA Response Amgen investors can finally breathe a little sigh of relief after the biopharma giant announces that the Food and Drug Administration has finally approved its blood disorder drug.
The Motley Fool July 30, 2007 Brian Lawler	Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.
The Motley Fool June 19, 2007 Brian Lawler	Victory for Sanofi and Bristol-Myers The pharmaceutical gains a crucial legal victory for its top compound. Investors, take note.
The Motley Fool August 18, 2011 Brian Orelli	A Poke in the Eye From the FDA FDA extends its review of Regeneron Pharmaceuticals' macular degeneration drug by three months.
InternetNews August 28, 2009	Dell, HP Side With Microsoft on Word Appeal Microsoft gained some help this week from its two largest PC partners who asked the court to let them join in the company's Word lawsuit as so-called "friends of the court."
BusinessWeek June 4, 2007 Gene G. Marcial	Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled.
The Motley Fool March 19, 2008 Brian Lawler	Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera.
The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool April 28, 2008 Brian Lawler	Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.
The Motley Fool June 23, 2005 Brian Gorman	Amgen's Drug-Approval Dilemma A recent lawsuit illustrates drugmakers' difficult position. Even conservative drug-stock investors could be in for a bumpy ride.
The Motley Fool January 23, 2004 Alyce Lomax	Amgen's Engine Is the drug company geared up for success?
The Motley Fool November 9, 2006 Karl Thiel	The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note.
The Motley Fool April 11, 2008 Brian Lawler	Amgen's Unsurprising Delay The FDA extends its review of an Amgen drug candidate.
The Motley Fool October 3, 2008 Brian Orelli	Amgen Draws Blood in Anemia-Drug War The pharmaceutical fights off rival Roche.
The Motley Fool September 28, 2006 Brian Lawler	Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note.
The Motley Fool February 20, 2007 Brian Lawler	Sanofi Sweats the Generic Drugmaker Sanofi-Aventis releases fourth-quarter earnings numbers and guidance for the year ahead.
The Motley Fool July 12, 2011 Brian Orelli	That's One Expensive BiTE Amgen licenses Micromet's BiTE antibody technology.
The Motley Fool September 1, 2006 Brian Lawler	Bristol-Myers and Sanofi Get Apotex to Stop A temporary injunction against generic drug manufacturer Apotex over patents involving Plavix means big news for all the companies involved.
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool July 21, 2006 Brian Lawler	Amgen's Little Helpers Sluggish earnings are offset by promising drugs in the pipeline. The bottom line with Amgen is that it is one of the best-run biotechs, period. Investors, take note.
The Motley Fool October 29, 2007 Brian Lawler	Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool July 14, 2011 Brian Orelli	Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial.
The Motley Fool June 20, 2011 Brian Orelli	See Drug, Approve Drug An approval of Regeneron's macular degeneration Eylea looks likely.
InternetNews March 3, 2006 Roy Mark	Trolling for Patents Patent infringement claims are easy to make and difficult to disprove.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool October 24, 2006 Brian Lawler	Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend.
Chemistry World December 17, 2015 Sarah Houlton	Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market.
Pharmaceutical Executive November 1, 2012	Pharm Exec's 2013 Pipeline Report In this year's report, Ben Comer reveals that drug approvals are up, as new discoveries in biology peel away symptomology to expose underlying causes.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
The Motley Fool May 14, 2007 Mike Havrilla	A Weaker Amgen Amgen's stock is trading lower after an FDA panel balked at two anemia drugs.